Efficacy comparison of GP regimen or gemcitabin treated for elderly patients with advanced nonsmall-cell lung cancer
10.3760/cma.j.issn.1006-9801.2012.03.012
- VernacularTitle:GP方案与吉西他滨单药治疗老年人晚期非小细胞肺癌的疗效比较
- Author:
Xinyan ZHAO
;
Yanhong YANG
- Publication Type:Journal Article
- Keywords:
Arcinoma,non-small-cell lung;
Aged;
Gemcitabin;
Cisplatin;
Antineoplastic combined chemotherapy protocols
- From:
Cancer Research and Clinic
2012;24(3):186-188
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate and compare the efficacy and toxicity of gemcitabin(GEM) plus cisplantin and GEM on the chemotherapy of elderly patients advanced non-small-cell lung cancer (NSCLC).Methods 85 elderly patients with stage 3 to 4 NSCLC were randomized into gemcitabine plus cisplatin (group GP) and GEM (group GEM).In group GP,patients received GEM on day 1 and day 8 at dose 1.0 g/m2,add cisplatin on day 2 to day 4 at dose 75 mg/m2. In group GEM, patients would received single GEM at dose 1.25 g/m2.The the therapy circle was 3 weeks and undertaken least 2 circles before the treatment efficacy and survival would be evaluated according RECIST. Results In GP group the response rate was 48.84 ％(21/43),In GEM group the response rate was 35.71％(15/42),the difference of response rate between two groups was not statistically significant(x2=1.708,P=0.424).The median survival were 11 months to Gp group and 9 months to GEM group. The 1 year survival rates of GP group were 39.53 ％ and of GEM group were 26.19 ％. The survival time between two groups was not statistically significant(t=1.377,P=0.172).The same toxicity in both groups was defected, Nausea and vomiting occurred were more serious in GP group than that in GEM group (x2=9.796, P=0.002). Conclusion GP and GEM are both effective for treatment of elderly advanced NSCLC.There are no significantly differences on efficacy and toxicity in 2 groups. Side effects on alimentary system are obviously less in GEM group than that in GP group.
